Cxcr4 agonist treatment of hematopoietic cells

Details Cxcr4 agonist treatment of hematopoietic cells Cxcr4 agonist treatment of hematopoietic cells

A - Human Necessities

61

K

A61K 38/10 (2006.01) A61K 38/16 (2006.01) A61P 35/00 (2006.01) A61P 37/00 (2006.01)

Patent

CA 2405907

In accordance with various aspects of the invention, CXCR4 agonists, including SDF-1 polypeptides and SDF-1 polypeptide homologues, may be used in reducing the rate of hematopoietic cell multiplication. Methods of the invention may comprise administration of an effective amount of an CXCR4 agonist to cells selected from the group consisting of hematopoietic stem cells and hematopoietic progenitor cells. Cells may be treated in vitro or in vivo in a patient. A therapeutically effective amount of the CXCR4 agonist may be administered to a patient in need of such treatment. Patients in need of such treatments may include, for example patients requiring bone marrow or peripheral blood stem cell transplantation.

Conformément à divers aspects de cette invention, des agonistes de CXCR4, notamment des polypeptides SDF-1 et des homologues de polypeptides SDF-1, peuvent être utilisés pour la réduction du taux de multiplication des cellules hématopoïétiques. Des procédés de cette invention peuvent comprendre l'administration d'une quantité efficace d'un antagoniste de CXCR4 à des cellules choisies dans le groupe comprenant des cellules souches hématopoïétiques et des cellules primordiales hématopoïétiques. Les cellules peuvent être traitées in vitro ou in vivo dans un patient. Une quantité thérapeutiquement efficace dudit agoniste de CXCR4 peut être administrée à un patient dont la condition nécessite un tel traitement. Des patients dont la condition exige de tels traitements peuvent comprendre par exemple, des patients nécessitant une greffe de moelle osseuse ou une greffe de cellules souches du sang périphérique.

Affiliated with

Also associated with

Rating

Cxcr4 agonist treatment of hematopoietic cells does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cxcr4 agonist treatment of hematopoietic cells, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cxcr4 agonist treatment of hematopoietic cells will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1926573